Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Human Cardiomyocytes

October 5, 2010 8:29 am | Product Releases | Comments

GE Healthcare announces the availability of human cardiomyocytes that provide a more readily available and biologically-relevant alternative to current cell models and primary cells used in drug discovery and predictive toxicity testing.

TOPICS:

Biocontainers

October 5, 2010 8:25 am | Product Releases | Comments

TepoFlex biocontainers provide secure, robust fluid handling options. TepoFlex polyethylene-based biocontainers are available in 2D end-ported designs from 250 mL to 20 L and 2D face-ported designs from 5 L-200 L.

TOPICS:

Isogenica Collaborating With NovaBiotics

October 5, 2010 8:12 am | News | Comments

Isogenica Ltd, announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of Novabiotic’s anti-infective peptide technology platform.

TOPICS:
Advertisement

Evotec In Deal With Shionogi

October 5, 2010 8:08 am | News | Comments

Evotec AG announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd. to identify small molecule modulators of various protein-protein interaction targets.

TOPICS:

Onconova And FDA Agree on Phase 3 Trial Design

October 5, 2010 8:05 am | News | Comments

Onconova Therapeutics, Inc. announced agreement with the FDA regarding an SPA for the design of a pivotal Phase 3 trial for Estybon as monotherapy in patients with myelodysplastic syndromes, diseases affecting the production of healthy blood cells.

TOPICS:

PROLOR Receives Orphan Drug Designation

October 5, 2010 7:55 am | News | Comments

PROLOR Biotech, Inc. announced that the FDA has granted orphan drug designation to hGH-CTP, PROLOR’s longer-acting version of human growth hormone for the treatment of growth hormone deficiency. hGH-CTP is currently in a Phase 2 clinical trial.

TOPICS:

X-Rays Linked to Childhood Leukemia

October 5, 2010 7:40 am | News | Comments

Researchers have discovered that children with acute lymphoid leukemia had almost twice the chance of having been exposed to three or more X-rays compared with children who did not have leukemia.

TOPICS:

Possible Biomarker for Seizure-related Stress

October 5, 2010 7:36 am | News | Comments

New research has found that reduced levels of brain-derived neurotrophic factor, a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with seizures that are psychological in origin.

TOPICS:
Advertisement

Promising Start for New Osteoporosis Drug

October 5, 2010 7:31 am | News | Comments

Researchers have discovered a group of substances in the body that play a key role in controlling bone density, and on this basis they have begun development of a drug for prevention and treatment of osteoporosis and other bone disorders.

TOPICS:

Inflammation Helps Heal Wounds

October 5, 2010 7:28 am | News | Comments

A new research study may change how sports injuries involving muscle tissue are treated, as well as how much patient monitoring is necessary when potent anti-inflammatory drugs are prescribed for a long time.

TOPICS:

Brain Cancer Vaccine Extends Survival

October 5, 2010 7:24 am | News | Comments

A new vaccine added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma, the most deadly form of brain cancer. The vaccine knocks out a growth factor that characterizes the most aggressive form of the disease.

TOPICS:

Norian Paying Maximum Fine for Unapproved Trials

October 5, 2010 7:09 am | by Maryclaire Dale | News | Comments

A Pennsylvania medical devices company will pay the maximum $23 million fine for illegally testing bone cement on about 200 spinal patients, three of whom died during surgery.

TOPICS:

Tris Pharma Marketing Generic Tussionex

October 5, 2010 7:05 am | News | Comments

Tris Pharma, Inc., has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for a generic version of UCB's Tussionex, which is used for relief of cough and upper respiratory symptoms associated with allergy or a cold.

TOPICS:

Breakdown of Sanofi-Genzyme Deal

October 5, 2010 7:01 am | News | Comments

Here's how French pharmaceutical giant Sanofi-Aventis SA, which has initiated a hostile takeover attempt for Genzyme Corp. of Cambridge, Mass., describes how the proposed $18.5 billion deal would benefit the two companies and their shareholders.

TOPICS:

Merck Wants Fosamax Verdict Overturned

October 5, 2010 6:56 am | News | Comments

Merck & Co. says it will seek a new trial or even a ruling in its favor after a federal judge slashed the jury verdict against the drugmaker in the case of a woman alleging Merck's osteoporosis drug severely damaged her jaw.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading